Participants must present a secondary endocrine resistance to endocrine therapy defined as progression while on endocrine therapy after at least 6 months of treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy but after the first 2 years, or with a relapse within 12 months after completing adjuvant endocrine therapy
lasix to torsemide conversion
